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Abstract In autoimmune inflammatory diseases, including
juvenile idiopathic arthritis (JIA), which leads to joint destruc-
tion, there is an imbalance between production of reactive
oxygen species (ROS) and their neutralization which, as a
consequence, leads to “oxidative stress.” The aim of the study
was to assess the concentration of oxidative stress markers:
nitric oxide (NO), a degree of lipid membrane damage, and
total antioxidant plasma capacity in children with JIA. Thirty-
four children with JIAwere included into the study. A degree
of lipid membrane damage (lipid peroxidation products) was
estimated as thiobarbituric acid-reactive substances (TBARs),
NO concentration as NO end-products: nitrite/nitrate
(NO2
−/NO3
−) and total antioxidant plasma capacity as ferric
reducing ability of plasma (FRAP). NO2
−/NO3
− serum con-
centration in children with JIA was statistically significantly
higher than that in healthy children (p=0.00069). There was
no significant difference in TBAR levels between children
with JIA and the control group. FRAP in sera of children with
JIAwas lower than that in healthy children, but the difference
was not statistically significant. A statistically significant
positive correlation was observed between NO end products
and the 27-joint juvenile arthritis disease activity score
(JADAS-27) and ESR, and a negative correlation was ob-
served between FRAP and C-reactive protein (CRP) and
white blood cell count (WBC). Our results confirm the in-
creased oxidative stress in children with JIA. Overproduction
of NO and decrease in the antioxidant plasma capacity may be
involved in JIA pathogenesis.
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Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of
autoimmune diseases of unknown origin, with onset before
the age of 16 years. JIA is considered to be the most common
connective tissue disease of childhood. It is characterized by
leukocyte infiltration in the synovium leading to a chronic
inflammation in the joints, which persists for more than
6 weeks, with consequent destruction of articular tissue
[1, 2]. Recently, considerable interest has been generated in
determining the JIA pathogenesis, looking for new therapeutic
strategies and for the prognostic factors, which would permit
an early identification of patients with a poor prognosis,
justifying the application of an aggressive treatment in the
early stages of the disease [2, 3].
Reactive oxygen species (ROS) play a pivotal role in phys-
iological processes. ROS mediate and regulate many cell func-
tions, including cytokine production, signal transduction, mi-
tochondrial functions, immune processes, gene expression, and
apoptosis. The effects of ROS depend on their serum concen-
tration. Nitric oxide (NO), a unique biological messenger
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molecule, is a short-lived gaseous free radical. It is synthesized
from L-arginine by NO synthase in various cell types such as
chondrocytes, synoviocytes, and leukocytes, e.g., phagocytic
neutrophils. Direct measurement of NO and other free radicals
in standard laboratories is difficult because of their biochemical
instability. Due to the above, concentrations of NO end-prod-
ucts nitrite/nitrate (NO2
−/NO3
−) or the activity of NO synthase
is usually evaluated. NO is involved in immune regulation,
neurotransmission, and vasodilatation. Recently, the imbal-
ance between formation of ROS and body antioxidant de-
fense in homeostasis disturbances is widely discussed [4].
The currently reported data demonstrated a significant role
of ROS in the etiopathogenesis of autoimmune diseases. In
chronic inflammatory processes, after long stimulation, the
exhaustion of the body’s antioxidative reserves results in a
harmful activity of ROS, as they gain an advantage over the
antioxidant system—this phenomenon is called “oxidative
stress” [5].
Many studies are conducted on the role of ROS in the
etiopathogenesis of rheumatoid arthritis (RA), which seem
to be a main direct factor destroying the joint tissues, but in
the pediatric population with JIA, their role has still not been
elucidated [5–9]. It could be hypothesized that patients with
JIA have defective defense mechanisms against ROS and
these mechanisms vary according to the JIA subtypes.
The aim of the study was to assess markers of the oxidative
stress: concentrations of NO end-products nitrite/nitrate
(NO2
−/NO3
−), thiobarbituric acid-reactive substances
(TBARs), and total antioxidant capacity of plasma via ferric
reducing ability of plasma (FRAP) in the sera of children with
JIA in comparison with healthy children. Moreover, the study
also aimed to correlate these markers with disease character-
istics (type of JIA onset, disease activity).
Patients and methods
Patients
Thirty-four children (22 girls, 12 boys) with JIAwere included
into the study. The patients were entered in regard to the 2001
International League Against Rheumatism (ILAR) classifica-
tion criteria [10]. Twenty-six children had polyarticular JIA
type of onset, and eight had oligoarticular JIA. They were
aged 7–18 years (mean 13.8±1.2 years, range 7–18), had
disease duration time of 0.5–7.5 years (mean 3.5±0.8 years),
and were treated with DMARDs (methotrexate, 28 patients or
sulfasalazine, 6 patients) and low doses of steroids (predni-
sone <10 mg/day). All of the study group children were
biologically naive (Table 1).
Twenty sex- and age-matched healthy children (without
autoimmune diseases) from the control group were also
examined.
Serum samples (3 mL) were obtained simultaneously with
routine laboratory tests (white blood cell (WBC) count, red
blood cell (RBC) count, thrombocyte count, hemoglobin, C-
reactive protein (CRP)). The activity of the rheumatoid pro-
cess was assessed according to the 27-joint juvenile arthritis
disease activity score (JADAS-27) [11]. Each patient was
evaluated for the physician’s global assessment of overall
disease activity, which was measured on a 10-cm visual
analog scale (VAS; 0=no activity and 10=maximum activity);
parent’s global assessment of the child’s overall well-being,
which was measured on a 10-cm VAS (0=very good and 10=
very poor); and 27-joint count including the cervical spine,
elbows, wrists, metacarpophalangeal joints (from the first to
the third), proximal interphalangeal joints, hips, knees, ankles,
and ESR.
The study was approved by the local ethical committee. In
every case, a written informed consent was obtained from the
patient and parents before study entry.
Methods
NO assay
The concentration of NO was assessed with an indirect
method by measurement of NO end-products nitrite/
nitrate (NO2
−/NO3
−) (Nitrate/Nitrite Colorimetric Assay
Kit, Sigma-Aldrich Chemie GmbH, Switzerland). Total
Table 1 Demographic, clinical, and laboratory parameters of children
with JIA
Characteristics of children with JIA (n=34)
Female/male, n (%) 22/12 (64.7/35.3)
Age (years)/range 13.8±1.2/7–18
Type of JIA onset
Polyarticular, n (%) 26 (76.5)
IgM-RF-negative 24
IgM-RF-positive 2
Oligoarticular, n (%) 8 (23.5)
Persistent oligoarticular JIA 7
Extended oligoarticular JIA 1
Disease duration time (years) 3.5±0.8
ESR (mm/h) 19.4±20.5 (median 10)
ESR above cutoff value (>20 mm/h), n (%) 8 (23.5)
CRP (mg/dL) 2.67±6.26 (median 0.39)
CRP above cutoff value (>0.5 mg/dL), n (%) 14 (41.2)
IgM-RF positivity (≥24 RU/mL), n (%) 2 (5.9)
Disease activity
JADAS-27 23.94±10.10 (median 25)
Data are means ± standard deviation (SD), unless otherwise indicated
n number of children, ERS erythrocyte sedimentation ratio, CRP
C-reactive protein
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NO2
−/NO3
− concentrations in the serum samples were de-
termined by microcolorimetric Griess reaction for nitrite
[12] following nitrate reductase-mediated nitrate ion
reduction [13]. The absorbance of the chromophore was read
at a wavelength of λ=548 nm.
Determination of TBARs
Measurement of lipid peroxidation products was based on
thiobarbituric acid-reactive substance (TBAR) concentration
in plasma. Briefly, 1 mL of 0.05 mol/L H2SO4 and 0.5 mL of
1.23 mol/L trichloroacetic acid (TCA) were added to 0.02 mL
of plasma, mixed, and then centrifuged for 10 min (1,500×g,
20 °C). Fluorescence was measured at an excitation wave-
length of λ=515 nm and emission wavelength of λ=546 nm.
FRAP assay
The total antioxidant plasma capacity was assayed in terms of
the ferric reducing ability of plasma (FRAP) according to the
original description by Benzie and Strain [14]. This method
measures the ability of antioxidants contained in a sample to
reduce ferric tripyridyltriazine (Fe3+-TPTZ) to a ferrous form
(Fe2+-TPTZ) that absorbs light at λ=593 nm.
Statistical analysis
Data was expressed as mean and standard deviation (±SD).
Results were analyzed using nonparametric Mann-Whitney
tests, and correlation was found by the Spearman coefficient.
Confidence level was 95 % and statistical significance was
considered at a level of 0.05.
Results
The demographic, clinical, and laboratory features of children
with JIA are shown in Table 1.
NO assay/concentration of NO2
−/NO3
−
Figure 1 shows higher serum concentrations of NO end-prod-




− concentrations in the serum samples of
34 children with JIA were significantly higher (9.59±
4.14μmol/L) than those measured in sera of 20 sex- and
age-matched children from the control group (5.59±
2.25 μmol/L; p=0.00069). There was no statistically signifi-
cant difference in serum NO2
−/NO3
− concentrations between
children with polyarthritis and oligoarthritis (p>0.05)
(Table 2).
A positive correlation was observed between NO2
−/NO3
−
concentrations and JADAS-27 and ESR (R=0.542, p=0.039;
R=0.621, p=0.009).
Determination of TBARs
There were no statistically significant differences in TBAR
levels between children with JIA and the control group
(0.59±0.2 and 0.61±0.18 μmol/L, respectively) (Table 2).
No statistically significant difference was observed in se-
rum TBAR levels between children with polyarthritis and
oligoarthritis (p>0.05).
TBARs did not correlate with either clinical or laboratory
variables of disease activity.



















   
   
   
   
   
   
   





]Fig. 1 Nitrite/nitrate (NO2
−/NO3
−)
serum concentration and mean
value (horizontal line) in children
with JIA and in the control group
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FRAP assay
In the group of children with JIA, FRAP was lower (0.75±
0.1 mmol/L) than in healthy subjects (0.89±0.17 mmol/L,
p=0.048) (Fig. 2). However, no statistically significant differ-
ence was observed in serum FRAP levels between children
with polyarthritis and oligoarthritis (p>0.05).
Furthermore, statistically significant negative correlations
betweenWBC vs. FRAP levels (R=−0.583, p=0.013) as well
as CRP vs. FRAP levels (R=−0.633, p=0.0064) in the group
of children with JIAwere detected.
No statistically significant correlations were detected be-
tween distribution of NO end-products, TBARs, and FRAP
according to sex, age, and treatment.
Discussion
Proinflammatory factors such as cytokines and prostaglandins
are released at inflammation sites together with ROS [15].
Several studies in patients with RA have documented
evidence for increased endogenous NO synthesis, suggesting
that overproduction of NO in an inflamed joint may be im-
portant for the pathogenesis of RA, but in JIA its role is still
unclear [5–9, 16]. To the best of our knowledge, this is the first
study assessing the NO end-products nitrite/nitrate, the index
of lipid peroxidation (TBARs), and the total antioxidant plas-
ma capacity (FRAP) in children with JIA.
The currently reported data with adult RA patients and
confirmed in animal models indicated that NO may func-
tion as a disease marker and as a proinflammatory medi-
ator in arthritis [6–9]. Regarding the pathogenesis of RA,
it seems that excessive oxidative stress in the inflamed
joints is reflected as an increased concentration of NO in
peripheral blood [16]. Our study demonstrated a statisti-
cally significant increase in serum concentration of NO2
−/
NO3
− in children with JIA compared to healthy subjects,
which is in concordance with results obtained by Lotito
et al. and Beri et al. [17, 18].
Similarly to other studies, there was no significant differ-
ence in NO levels among two JIA subtypes (poly- and
oligoarthritis) in our study group [18–20].
Similarly to Bica et al. and Lotito et al., we showed that the
concentration of NO end-products in sera of children with JIA
and active disease was higher than that in children with
inactive process, however without a statistically significant
difference [3, 17]. Our study indicated a significant positive
correlation between JADAS-27 and ESR and NO end-
products’ levels, which is in concordance with previous au-
thors’ observations in adult patients with RA; however, in JIA
such correlations were not found [3, 9, 18]. On the other hand,
it was observed by Bica et al. that patients with active JIA and
erosive disease had significantly higher NO levels, whereas
Table 2 Concentration of nitrite/nitrate (NO2
−/NO3
−), thiobarbituric
acid-reactive substance (TBARs), and the ferric reducing ability of plas-








− (μmol/L) 9.59±4.14 5.59±2.25 0.00069
TBARs (μmol/L) 0.59±0.2 0.61±0.18 0.836
FRAP (mmol/L) 0.75±0.1 0.89±0.17 0.048













   
   
   
   
   
   
   
   
   





]Fig. 2 FRAP serum
concentration and mean value
(horizontal line) in children with
JIA and in the control group
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children with an inactive rheumatoid process had similar NO
levels regardless of whether erosions were present or not [3].
There is no compliance among authors about the serum
concentration of lipid peroxidation products measured as
TBARs in children with JIA. However, it is well established
that overproduction of ROS in pathological processes, like
chronic inflammation, could result in oxygenation of cell
membrane compounds (protein structure damage, lipid oxida-
tion), thus inducing loss of cell integrity and functional alter-
ation of cell receptors and enzymes [15]. In our group of
children with JIA, no statistically significant difference was
detected in the concentration of TBARs either between the
two JIA subtypes and healthy subjects, which is in line with
previous observations of other authors [20]. In contrary, in
another study, increased TBARs were found in sera of chil-
dren with JIA [21]. Ramos et al. also observed such correla-
tions; however, the authors determined different products of
lipid peroxidation than we did [19]. Guney et al. who deter-
mined malonodialdehyde (MDA) by thiobarbituric acid test
indicated higher MDA levels in patients with JIA, with the
highest concentration in systemic JIA [15]. The discrepancies
between studies may be also explained by the fact that TBARs
are not a very specific marker, and perhaps it would be better
to determine specific substances like MDA and lipoperoxide
(LPO). Furthermore, patients with rheumatoid process have
defective defense mechanisms against ROS [6–9, 22, 23]. It
was also proved that inflammatory immune response is upon
aging [4, 24]. Perhaps, it could be speculated that similar
levels of TBARs in healthy children and those with JIA could
be explained by high efficiency of the antioxidant system in
children, as well as higher cell membrane stability in young
subjects and less susceptibility of the membrane’s components
to damaging factors [15].
It is worth noticing that this is the first study on FRAP in
children with JIA. Among various methods, assessing the
antioxidant capacity of plasma FRAP, which estimates the total
antioxidant plasma capacity, seems to be the best, as it gathers
whole scavenging abilities of plasma. It is still undecided if a
lower level of FRAP is the cause or effect of rheumatoid
process. Sarban et al. have described decreased levels of the
antioxidant plasma capacity assayed in terms of FRAP in RA
patients and postulated that decreased FRAP could contribute
to the pathogenesis of rheumatoid process [23]. Although there
was no statistically significant difference in FRAP levels, com-
parison of our study and control groups indicated that FRAP
was lower in sera of children with JIA. Perhaps, a small
difference between FRAP levels in the study and control
groups was due to the efficient defense against ROS in young
patients with JIA or an effective anti-inflammatory therapy of
JIA that results in adaptive increase of FRAP [25]. Although
there was no significant correlation of FRAP with disease
activity, it should be underlined that FRAP negatively corre-
lates with CRP and WBC in children with JIA.
Conclusions
The results provide some evidence for a potential role of the
increased NO and decreased antioxidant plasma capacity in
the pathogenetic mechanism of JIA. Measurement of NO and
FRAPmay provide a useful tool to aid in the assessment of the
patient’s oxidative stress status and in the determination of an
appropriate treatment management plan. Further studies are
needed to determine the exact role of ROS and particularly
NO in the pathogenesis of JIA and to show its usefulness as a
marker of disease activity.
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